Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162240

SCHEMBL10162240

SCHEMBL10162240

CC(=O)C12CCC(CNC(=O)c3cc(C(=O)NCc4ccc(F)c(C)c4)nc4ncnn34)(CC1)CC2

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 10/20 0.48
▸ MMP10 P09238 2/20 0.43
▸ MMP8 P22894 2/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ADAMTS4 O75173 1/20 0.36
▸ MMP3 P08254 1/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ PDE2A O00408 3/20 0.35
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165934 0.94 MMP13 (0.48) MMP13MMP10MMP8MMP9MEN1
SCHEMBL10162242 0.94 MMP13 (0.39) MMP13MMP10MMP8MMP9MEN1
SCHEMBL10165625 0.92 MMP13 (0.47) MMP13MMP10MMP8MMP9MEN1
SCHEMBL10162252 0.91 MMP13 (0.40) MMP13PDE2A
SCHEMBL8253375 0.91 MMP13 (0.47) MMP13MMP10MMP8MMP9MEN1
SCHEMBL10162262 0.90 SMN1; SMN2 (0.38) MMP13ALDH1A1CYP3A4L3MBTL1
SCHEMBL10162263 0.90 MMP13 (0.45) MMP13MMP10MMP8MMP9MEN1
SCHEMBL8253321 0.89 MMP13 (0.46) MMP13MMP10MMP8MMP9MEN1
SCHEMBL10162185 0.88 MMP13 (0.47) MMP13MMP10MMP8MMP9ADAMTS4
SCHEMBL10162270 0.88 ALDH1A1 (0.33) MMP13MMP8MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP10 4/4885MMP8 26/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885MMP10 4/4885MMP8 26/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP10 4/4885MMP8 26/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP10 4/4885MMP8 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.